Literature DB >> 100050

UK-18892, a new aminoglycoside: an in vitro study.

R Wise, J M Andrews.   

Abstract

UK-18892 is a new aminoglycoside antibiotic, a derivative of kanamycin A structurally related to amikacin. It was found to be active against a wide range of pathogenic bacteria, including many gentamicin-resistant strains. The spectrum and degree of activity of UK-18892 were similar to those of amikacin, and differences were relatively minor. UK-18892 was about twice as active as amikacin against gentamicin-susceptible strains of Pseudomonas aeruginosa. Both amikacin and UK-18892 were equally active against gentamicin-resistant strains of P. aeruginosa. There were no appreciable differences in the activity of UK-18892 and amikacin against Enterobacteriaceae and Staphylococcus aureus. Cross-resistance between these two antimicrobials was also apparent.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100050      PMCID: PMC352438          DOI: 10.1128/AAC.14.2.228

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Enzymatic acetylation of aminoglycoside antibiotics by Escherichia coli carrying an R factor.

Authors:  R Benveniste; J Davies
Journal:  Biochemistry       Date:  1971-05-11       Impact factor: 3.162

2.  Discovery, chemistry, and activity of amikacin.

Authors:  H Kawaguchi
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

3.  Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives.

Authors:  K Richardson; S Jevons; J W Moore; B C Ross; J R Wright
Journal:  J Antibiot (Tokyo)       Date:  1977-10       Impact factor: 2.649

4.  Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.

Authors:  P M Sharp; C A Saenz; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

5.  Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.

Authors:  K E Price; M D DeFuria; T A Pursiano
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

6.  Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus.

Authors:  L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

  6 in total
  1 in total

1.  Pharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injury.

Authors:  J L Segal; S R Brunnemann; I M Eltorai
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.